Muhammad ShaalanBegMDMS

PubMed

• The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial.
  David Hsiehchen, Muhammad S Beg, Radhika Kainthla, Jay Lohrey, Syed M Kazmi, Leticia Khosama, Mary Claire Maxwell, Heather Kline, Courtney Katz, Asim Hassan, Naoto Kub...> ;Nature Communications. 2024 Mar 11
• Modernize Precision Oncology With Decentralized Trial Tools.
  Muhammad Shaalan Beg, Vivek Subbiah> ;JAMA Oncology. 2024 Apr 1
• Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.
  David Hsiehchen, Leslie Bucheit, Dong Yang, Muhammad Shaalan Beg, Mir Lim, Sunyoung S Lee, Pashtoon Murtaza Kasi, Ahmed O Kaseb, Hao Zhu> ;Nature Communications. 2023 Nov 22
• 3 citations
  Feasibility of institution-agnostic, EHR-integrated regional clinical trial matching.
  Sharon P Shriver, Waddah Arafat, Caroline Potteiger, Dorothy L Butler, Muhammad S Beg, Melanie Hullings, Salim Semy, Zach Lister, Leticia Khosama, Susan Armstrong, Dav...> ;Cancer. 2024 Jan 1
• Fibroblast growth factor receptor inhibitor therapy induced calcinosis cutis treated with sodium thiosulfate.
  Justin Qian, Jeffrey N Li, Elysha K Rose, Travis Vandergriff, Leticia Khosama, Muhammad S Beg, Melissa M Mauskar, Richard C Wang> ;JAAD Case Reports. 2023 Jan 1
• Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.
  David Hsiehchen, Leslie Bucheit, Dong Yang, Muhammad Shaalan Beg, Mir Lim, Sunyoung S Lee, Pashtoon Murtaza Kasi, Ahmed O Kaseb, Hao Zhu> ;Nature Communications. 2022 Dec 3
• A qualitative study to explore the acceptability and usefulness of personalized biofeedback to motivate physical activity in cancer survivors.
  Grace E Brannon, Madison Ray, Patrick Cho, Miranda Baum, Muhammad Shaalan Beg, Therese Bevers, Susan M Schembre, Karen Basen-Engquist, Yue Liao> ;Digital Health. 2022 Oct 9
• Trends in utilization of first-line palliative treatments for anal squamous cell carcinoma.
  Srinidhi J Radhakrishnan, Saikripa M Radhakrishnan, Muhammad S Beg, Nina N Sanford, Syed M Kazmi, Goksu, S.> ;Cancer Medicine. 2023 Feb 1
• 9 citations
  Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual-First Paradigm?
  Sherry Fu, David E Gerber, Muhammad Shaalan Beg> ;Journal of Clinical Oncology. 2023 Jan 10
• 4 citations
  Rural-Urban Disparities in Mortality and Place of Death for Gastrointestinal Cancer in the United States From 2003 to 2019.
  S M Qasim Hussaini, Amanda L Blackford, Nivedita Arora, Ramy Sedhom, Muhammad Shaalan Beg, Arjun Gupta> ;Gastroenterology. 2022 Dec 1
• 19 citations
  A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01.
  Vaibhav Sahai, Kent A Griffith, Muhammad S Beg, Walid L Shaib, Devalingam Mahalingam, David B Zhen, Dustin A Deming, Mark M Zalupski> ;Cancer. 2022 Oct 1
• 7 citations
  Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes.
  Ahmed M Elamir, John D Karalis, Nina Niu Sanford, Patricio M Polanco, Michael R Folkert, Matthew R Porembka, Syed Ali Kazmi, Ravikanth Maddipati, Herbert J Zeh, Robert...> ;International Journal of Radiation Oncology, Biology, Physics. 2022 Nov 15
• 3 citations
  Survival of cancer survivors with a new pancreatic cancer diagnosis.
  Sandi L Pruitt, Anna Tavakkoli, Hong Zhu, Daniel F Heitjan, Amit G Singal, Ethan A Halm, Muhammad Shaalan Beg, Bhumika Maddineni, Ankit J Kansagra, Caitlin C Murphy, G...> ;Cancer Medicine. 2023 Jan 1
• 3 citations
  Twitter Conversations About Pancreatic Cancer by Health Care Providers and the General Public: Thematic Analysis.
  Udhayvir Singh Grewal, Arjun Gupta, Jamie Doggett, Emil Lou, Niraj J Gusani, Anirban Maitra, Muhammad Shaalan Beg, Allyson J Ocean> ;JMIR Cancer. 2022 Mar 24
• 3 citations
  Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials.
  Timothy J Brown, Arjun Gupta, Ramy Sedhom, Muhammad S Beg, Thomas B Karasic, Mark Yarchoan> ;Gastrointestinal Tumors. 2022 Mar 1
• 9 citations
  A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer.
  Muhammet Ozer, Nina N Sanford, Matthew Porembka, Hajra Khurshid, Chul Ahn, Mary Claire Maxwell, Muhammad Shaalan Beg, Syed M Kazmi, Goksu, S.> ;JAMA Network Open. 2022 Feb 1
• 3 citations
  A Qualitative Examination of COVID-19's Impacts on Physical Activity and Perceptions of Remote Delivery Interventions.
  Grace Ellen Brannon, Sophia Mitchell, Madison A. Ray, Salman Bhai, Muhammad Shaalan Beg, Karen Basen-Engquist, Yue Liao> ;American Journal of Health Promotion. 2021 Nov 17
• 5 citations
  Age-dependent prognostic value of KRAS mutation in metastatic colorectal cancer.
  Muhammet Ozer, Suleyman Yasin Goksu, Nina N. Sanford, Chul Ahn, Muhammad Shaalan Beg, Syed Mohammad Ali Kazmi> ;Future Oncology. 2021 Nov 11
• 13 citations
  Time-Related Burdens of Cancer Care.
  Arjun Gupta, Eric H. Jensen, Beth A Virnig, Muhammad Shaalan Beg> ;JCO Oncology Practice. 2021 Oct 28
• 5 citations
  Current status and future perspectives on the Internet of Things in oncology.
  Ibrahim N. Muhsen, Omar W. Rasheed, Eiad Habib, Rakan Alsaad, Mohannad K. Maghrabi, Abdul Rahman, Douglas Sicker, William A. Wood, Muhammad Shaalan Beg, Anthony D. Sun...> ;Hematology/oncology and Stem Cell Therapy. 2021 Oct 18
• 14 citations
  Application of Information Technology to Clinical Trial Evaluation and Enrollment: A Review.
  Mitchell S. von Itzstein, Melanie Hullings, Helen G. Mayo, M. Shaalan Beg, Erin L Williams, David E. Gerber> ;JAMA Oncology. 2021 Oct 1
• 6 citations
  Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay.
  David Hsiehchen, Magdalena Espinoza, David E. Gerber, Muhammad Shaalan Beg> ;Cancer Biology & Therapy. 2021 Aug 14
• 10 citations
  Taking Tele Behind the Scenes: Remote Clinical Trial Monitoring Comes of Age During the COVID-19 Pandemic.
  Erin L Williams, Desiree L Pierre, Mary E Martin, Muhammad Shaalan Beg, David E. Gerber> ;JCO Oncology Practice. 2021 Aug 11
• 4 citations
  Importance of addressing malnutrition in cancer and implementation of a quality improvement project in a gastrointestinal cancer clinic
  Nicholas Levonyak, Mary P Hodges, Nicole Haaf, Timothy J. Brown, Shelli Hardy, Verca Mhoon, Radhika Kainthla, Muhammad Shaalan Beg, Syed Mohammad Ali Kazmi> ;Nutrition in Clinical Practice. 2021 Aug 2
• 4 citations
  Longitudinal Experience With and Impressions of COVID-19-Related Clinical Research Changes.
  David E. Gerber, Valerie L Clark, Thomas Sheffield, M. Shaalan Beg, Yang Xie, M. E. Blair Holbein, Celette Sugg Skinner, Simon J. Craddock Lee, Erin L Williams> ;JCO Oncology Practice. 2021 Jul 29
• Join now to see all

Journal Articles

• Feasibility of Wearable Physical Activity Monitors in Patients With Cancer  
  Gupta A, Stewart T, Bhulani N, Dong Y, Rahimi Z, Crane K, Rethorst C, Beg MS, JCO Clinical Cancer Informatics, 1/1/2018
• Impact of concurrent medication use on pancreatic cancer survival-SEER-Medicare analysis  
  Beg MS, Gupta A, Sher D, Ali S, Khan S, Gao A, Stewart T, Ahn C, Berry J, Mortensen EM, Am J Clin Oncol, 1/10/2017
• The Promise of Wearable Physical Activity Monitors in Oncology Practice  
  Beg MS, Gupta A, Stewart S, Rethorst C, Journal of Oncology Practice, 1/1/2017
• Plasma leptin levels and risk of incident cancer: Results from the Dallas Heart Study  
  Gupta A, Herman Y, Ayers C, Beg MS, Lakoski SG, Abdulla SM, Johnson DH, Neeland IJ, PLoS One, 1/1/2016
• Yttrium-90 radioembolization of hepatic metastases from colorectal cancer  
  Raval M, Bande D, Pillai AK, Blaszkowsky LS, Ganguli S, Beg MS, Kalva SP, Front Oncol, 1/1/2014
• Predictive factors for early aspiration in liver abscess  
  Khan R, Hamid SS, Abid S, Jafri W, Abbas Z, Islam M, Shah H, Beg MS, World J Gastroenterol, 1/1/2008
• Join now to see all

Abstracts/Posters

• Does timing of palliative care consults impact end-of-life health services utilization in pancreatic cancer patients?
  Bhulani N, Gao A, Gupta A, Ahn C, Paulk E, Houck S, Li JJ, Guenther CM, Kazmi MA, Beg MS, J Clin Oncol, 1/1/2018
• Impact of palliative care consults on racial disparity in do-not resuscitation (DNR) orders at an urban safety net hospital.
  Bhulani N, Gupta A, Paulk ME, Donnell K, Harvey V, Cox J, Cox JV, Verma UN, Sanjeevaiah A, Cheedella NK, Khosama L, Arriaga YE, Syed SK, Kazmi SA, Beg MS, J Clin Oncol, 1/1/2018
• A multi-center randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first line therapy for patients with advanced unresect...
  Sahai V, Griffith KA, Beg MS, Zalupski M, J Clin Oncol, 1/1/2018
• A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, admi...
  Sarantopoulos J, Beg MS, Fotopoulos G, Taverna JA, Anthony SP, Weitman SD, Warner SL, Mouritsen L, Bearss D, Smith S, Beever H, Khemka V, J Clin Oncol, 1/1/2018
• Interaction between regorafenib and warfarin therapy.
  Beg MS, Khosama L, Conley S, Arriaga YE, Syed SK, Karri S, Verma UN, J Clin Oncol, 1/1/2017
• SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma.
  Sohal D, McDonough SL, Ahmad SA, Gandhi N, Beg MS, Wang-Gillam A, Guthrie K, Lowy AM, Philip PA, Hochster HS, J Clin Oncol, 1/1/2017
• The effects of pioglitazone treatment on pancreatic cancer-related insulin resistance.
  Stern J, Arriaga YE, Gupta A, Verma UN, Karri S, Syed SK, Khosama L, Mansour JC, Scherer P, Beg MS, J Clin Oncol, 1/1/2017
• Phase 1 study of ARQ 761, a B-lapachone analog that promotes NQO1-mediated programmed cancer cell necrosis.
  Gerber DE, Bisen AK, Beg MS, Frankel AE, Fatunde O, Fattah F, Arriaga YE, Dowell J, Meek C, Bolluyt J, Sarode V, Luo X, Schwartz BE, Boothman DA, Leff R, J Clin Oncol, 1/1/2017
• Feasibility of wearable physical activity monitors in cancer patients (PAMCaP).
  Beg MS, Steart T, Gupta A, Dong Y, Rahimi Z, Paul T, Crane K, Rethorst C, J Clin Oncol, 1/1/2017
• Ensituximab (E) in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results of a phase I/II clinical trial.
  Ensituximab (E) in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results of a phase I/II clinical trial., J Clin Oncol, 1/1/2017
• Chemotherapy outcomes for unresectable and metastatic biliary tract cancers (BTC): Role of fluoropyrimidine (FP) chemotherapy--A retrospective analysis.
  Alattar ML, Levin P, Beg MS, Verma U, Arriaga Y, Syed SK, Karri S, J Clin Oncol, 1/20/2016
• First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.
  Beg MS, Hong DS, Sachdev JC, Brenner J, Borad MJ, Ho YL, Kim TY, Becerra C, Park K, Bader AG, Stoudemire J, Smith S, Kim S, Kang YK, J Clin Oncol, 1/20/2016
• Impact of concurrent medications use on outcome of pancreatic cancer: SEER Medicare analysis.
  Beg MS, Stewart T, Gao A, Ahn C, Berry J, Mortensen E, J Clin Oncol, 1/20/2016
• A prospective analysis of individual body fat depots and risk of developing cancer: Insights from the Dallas heart study.
  Gupta A, Pandey A, Ayers C, Beg MS, Lakoski SG, Vega GL, Grundy SM, Johnson DH, Neeland IJ, J Clin Oncol, 1/20/2016
• A liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.
  Hong DS, Kang YK, Brenner AJ, Sachdev JC, Ejadi S, Borad MJ, Kim TY, Lim HY, Park K, Becerra C, Bader AG, Stoudemire J, Smith S, Beg MS, J Clin Oncol, 1/20/2016
• A phase 2 study of NEO-102 (ensituximab), a novel chimeric monoclonal antibody, in adult patients (pts) with unresectable, metastatic colorectal cancer (mCRC).
  Kim RD, Azad NS, Morse M, Tan BR, Poplin E, Beatson MA, Mavroukakis S, Cui K, Arlen PM, Beg MS, J Clin Oncol, 1/20/2016
• A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma.
  Sohal D, McDonough SL, Ahmad SA, Gandhi N, Beg MS, Wang-Gillam A, Guthrie KA, Lowy AM, Philip PA, Hochster HS, J Clin Oncol, 1/20/2016
• Comprehensive genomic profiling (CGP) to assess mutational load in gastric and esophageal adenocarcinomas: Implications for immunotherapies.
  Frampton GM, Schrock AB, Chalmers ZR, Sun J, Ennis R, Gowen K, Beg MS, Rubinson DA, Yelensky R, Stephens PJ, Miller VA, Ross JS, Ali SM, Klempner SJ, J Clin Oncol, 1/1/2016
• Racial and sex disparities in changing trends of squamous cell cancer of the anus (SSCA).
  Gupta A, Zhu H, Christie A, Meyer JJ, Khan SA, Beg MS, J Clin Oncol, 1/1/2016
• A phase II therapeutic, open label, multi-center clinical trial of NPC-1C, a chimeric monoclonal antibody(mAb), in adults with chemotherapy refractory metastatic color...
  Kim RD, Azad NS, Morse M, Tan BR, Poplin E, Beatson MA, Mavroukakis S, Cui K, Arlen PM, Beg MS, J Clin Oncol, 1/1/2016
• Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC).
  Khan SA, Ci B, Gerber DE, McFadden DG, Beg MS, Xie Y, Kurian P, Cabanillas ME, Busaidy NL, Sherman SI, Heilmann A, Ross JS, Bailey M, Burtness B, Ali SM, J Clin Oncol, 1/1/2016
• A Phase I/IIA multicenter clinical trial of the chimeric monoclonal antibody NEO102 (NPC-1C) in adults with refractory pancreatic and colorectal cancer.
  Beg MS, Morse M, Patel SP, Azad NS, Mavroukakis S, Beatson M, Arlen PM, J Clin Oncol, 1/20/2015
• A multicenter randomized phase II study of NPC-1C (N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or lo...
  Duffy AG, Beg MS, Greten TF, Beatson MA, Mavroukakis S, Patel SPP, Morse MA, Arlen PM, J Clin Oncol, 1/20/2015
• A phase II multicenter study of the chimeric monoclonal antibody NEO102 (N) in adults with refractory colorectal cancer (CC).
  Beg MS, Morse M, Tan BR, Kim RD, Poplin E, Azad NS, Mavroukakis S, Beatson MA, Arlen PM, J Clin Oncol, 1/20/2015
• Versatile synergistic strategies for the treatment of pancreatic cancer using NQO1-bioactivatable drugs.
  Moore Z, Chakrabarti G, Huang X, Lyssiotis C2, Brekken R, Beg M, Gerson S, Deberardinis R, Boothman DA, Cancer Res, 1/1/2015
• Join now to see all

Lectures

• A phase II clinical trial of the phosphatidylserine targeting antibody, bavituximab, in combination with pembrolizumab in patients with advanced hepatocellular carcinoma. 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
• Use Social Media to increase your influence. 
  Alexandria, VA, 2018; Dallas, TX, 2018 - 1/1/2018
• Molecular Mechanisms of Pancreatic Cancer Metabolism 
  Plano, TX - 1/1/2018
• Molecular targeted therapies for colorectal cancer 
  Daytona Beach, FL - 1/1/2017
• NQO1 Mediated Kiss of Death therapy for pancreatic cancer 
  San Francisco, CA - 1/1/2017
• Pancreatic Cancer management at the VA 
  VAMC, Dallas, TX - 1/1/2017
• Challenges in Pancreatic cancer clinical Trials 
  Vanderbilt University, Nashville, TN - 1/1/2017
• Clinical trials design for locally advanced pancreatic Cancer 
  Boston, MA - 1/1/2016
• The role of maintenance chemotherapy in metastatic pancreatic cancer 
  Orlando, FL - 1/1/2016
• NQO1 �Kiss of Death�, clinical trial design. 
  San Diego, CA - 1/1/2016
• A Phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis 
  Barcelona, Spain - 1/1/2015
• Perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma. 
  Chicago, IL - 1/1/2015
• Clinical trial toxicity assessment and reporting 
  Dallas, TX - 1/1/2015
• Hepatocellular Cancer 
  Dallas, TX - 1/1/2015
• Exploiting the NQO1 �Kiss of Death� as a therapeutic strategy for Pancreatic cancer 
  MD Anderson Cancer Center, Houston, TX - 1/1/2015
• Colorectal Cancer Update 
  Austin, TX - 1/1/2014
• Colorectal Cancer 
  Dallas, TX - 1/1/2014
• Evidence based management of metastatic colon cancer 
  Elkhart, IN, 2014; Reno, NV, 2014 - 1/1/2014
• A Phase 1 study of MRX-34, first in human, first in class liposomal micro-RNA-34 
  San Diego, CA - 1/1/2014
• Impact of screening on presentation and survival of colorectal cancer 
  Cincinnati, OH - 1/1/2007
• Do racial differences predict survival amongst VA patients with colon cancer 
  Cincinnati, OH - 1/1/2006
• Join now to see all

Other

• Pancreatic cancer risks and solutions 
  Beg MS, Dr Oz Show
  1/1/2018
• Life Lessons From a Man With Stage 4 Pancreatic Cancer - Men's Health 
  Beg MS, Mens Health Magazine
  1/1/2017
• Promise of wearable activity monitors in oncology practice 
  Beg MS, American Society of Clinical Oncology JOP Podcast
  1/1/2017
• Is wearable technology coming of age in Oncology? 
  Beg MS, ASCO Post
  1/1/2017
• Doctor discusses colon cancer screening- Television Interview 
  Beg MS, NBC DFW News
  1/1/2017
• Plugged In To DFW-CBS Dallas: Pancreatic cancer awareness television interview 
  Beg MS, CBS Dallas
  1/1/2017
• Doctor Joins Volunteers in Fighting for Our Cause 
  Beg MS, Volunteer Appreciation Month
  www.pancan.org
  1/1/2016
• UT Southwestern docs using South American tree to fight tumors- Television interview 
  Beg MS, WFAA News
  1/1/2016
• GI Cancers Symposium 2015: Colorectal Carcinoma abstracts review for 
  Beg MS, MedTALKS Oncology TV
  1/1/2015
• Mipsagargin Phase 2 Abstract Review. (Video interview) 
  Beg MS, GenSpera, Inc
  1/1/2015
• Pancreatic cancer awareness television interview 
  Beg MS, CBS Dallas-Plugged In To DFW-CBS Dallas
  1/1/2015
• If you�re over 50, it�s time for a colonoscopy 
  Beg MS, UTSW Blog Stories and Insights
• 8 common myths about colon cancer 
  Beg MS, UTSW Blog Stories and Insights
• What to expect if you have colon cancer 
  Beg MS, UTSW Blog Stories and Insights
• Joining together to fight pancreatic cancer 
  Beg MS, UTSW Blog Stories and Insights
• How does nutrition affect pancreatic cancer? 
  Beg MS, UTSW Blog Stories and Insights
• Processed meat and cancer: What�s the real risk? 
  Beg MS, UTSW Blog Stories and Insights
• 10 years of surviving colon cancer: Charles� story 
  Beg MS, UTSW Blog Stories and Insights
• 6 ways millennials and Gen Xers can reduce their colorectal cancer risk 
  Beg MS, UTSW Blog Stories and Insights
• Join now to see all